12 research outputs found
Prospective, multicenter, observational analysis of 5-HT3 receptor antagonist antiemetic prescribing with different chemotherapy regiments
Is pain in patients with haematological malignancies under-recognised? The results from Italian ECAD-O survey.
No abstract availabl
The ECAD_O project: clinical caring epidemiology of pain in the hospital: the nurses' contribution
Impact of setting of care on pain management in patients with cancer: a multicentre cross-sectional study
BACKGROUND: No study has so far addressed whether differences do exist in the management of cancer-related pain in patients admitted to oncology and non-oncology settings.PATIENTS AND METHODS: A multicentre cross-sectional study in 48 Italian hospitals has enrolled 819 patients receiving analgesic therapy for cancer-related pain. Demographics and clinical and analgesic therapy information have been prospectively collected by standardized forms. Adequacy of pain management has been evaluated by the Pain Management Index (PMI).RESULTS: Differences in the analgesic drug administration according to settings of care have been evident, non-opioids more frequently being administered in non-oncology units (19.6% versus 7.0%; P < 0.0001), while strong opioids are more frequently used in the oncology units (69.5% versus 51.9%; P < 0.0001). The number of patients receiving inadequate therapy (PMI < 0) has lowered in oncology compared with non-oncology units (11.3% versus 18.8%; P = 0.0024). Results of multiple logistic regression analysis have shown that the admission to non-oncology setting [odds ratio (OR) = 1.75, 95% confidence interval (CI) = 1.15-2.67; P = 0.0096] and the absence of metastatic disease (OR = 1.60, 95% CI = 1.04-2.44; P = 0.0317) were independent factors associated with an increased risk of receiving an inadequate analgesic therapy.CONCLUSION: Oncology wards provide the most adequate standard of analgesic therapy for cancer-related pain
Impact of early access to a palliative/supportive care intervention on pain management in patients with cancer.
BACKGROUND: No study has so far addressed whether differences do exist in the management of cancer pain between patients receiving usual care by primary specialists and those receiving early palliative/supportive intervention.PATIENTS AND METHODS: A multicentre cross-sectional study in 32 Italian Hospitals has included 1450 patients, receiving analgesic therapy for cancer pain: 602 with access to primary specialist alone (standard care, SC) and 848 with early access to a palliative/supportive care (ePSC) team, concomitant with primary oncology care.RESULTS: Statistically significant differences in the analgesic drug administration according to care model have been evident: non-opioids were more frequently used in SC (9.5% versus 2%; P < 0.001), while strong opioids in ePSC group (80% versus 63%; P < 0.001). The number of patients with severe pain was lower in ePSC compared with SC group (31% versus 17%; P < 0.001). Results of multivariate analysis have shown that ePSC integrated with primary oncologic care (relative risk 0.69; 95% confidence interval 0.48-0.99; P = 0.045) was an independent factor associated with a 31% reduced risk of suffering from severe pain.CONCLUSIONS: An ePSC team provides the most effective standard of analgesic therapy for cancer pain. A randomized clinical trial is needed to confirm these findings
Randomized trial of low-dose morphine versus weak opioids in moderate cancer pain
Purpose
The WHO guidelines on cancer pain management recommend a sequential three-step analgesic
ladder. However, conclusive data are lacking as to whether moderate pain should be treated with
either step II weak opioids or low-dose step III strong opioids.
Patients and Methods
In a multicenter, 28-day, open-label randomized controlled study, adults with moderate cancer pain were
assigned to receive either a weak opioid or low-dose morphine. The primary outcome was the number of
responder patients, defined as patientswith a 20% reduction in pain intensity on the numerical rating scale.
Results
A total of 240 patients with cancer (118 in the low-dose morphine and 122 in the weak-opioid group)
were included in the study. The primary outcome occurred in 88.2% of the low-dose morphine and in
57.7% of the weak-opioid group (odds risk, 6.18; 95% CI, 3.12 to 12.24; P,.001). The percentage of
responder patients was higher in the low-dose morphine group, as early as at 1 week. Clinically
meaningful ( 50%) pain reduction from baseline was significantly
higher in the low-dose morphine group (P , .001). A change in the assigned treatment occurred
more frequently in the weak-opioid group, because of inadequate analgesia. The general condition of
patients, which was based on the Edmonton Symptom Assessment System overall symptom
score, was better in the morphine group. Adverse effects were similar in both groups.
Conclusion
In patients with cancer and moderate pain, low-dose morphine reduced pain intensity significantly
compared with weak opioids, with a similarly good tolerability and an earlier effect